![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
SUMMARY
Objective: To compare the efficacy of lenograstim and filgrastim on haematological recovery following an autologous peripheral blood stem cell transplantation (PBSCT) with high-dose chemotherapy.
Methods: A retrospective case-controlled study.
Results: Absolute neutrophil count (ANC) recovery above 0.5 × 109 l−1 and white blood cell (WBC) recovery above 4 × 109 l−1 for 3 consecutive days was achieved earlier with filgrastim than with lenograstim ((13.2 ± 8.0 vs 19.0 ± 10.0 days, p = 0.004), (16.9 ± 9.7 vs 29.9 ± 16.6 days, p = 0.001), respectively). The platelet recovery above 20 x 109/l was also achieved earlier with filgrastim than with lenograstim (19.5 ± 11.6 vs
27.2 ± 13.8 days, p = 0.006). Furthermore, filgrastim-treated patients received fewer days of granulocyte colony simulating factor (G-CSF) administration (12.5 ± 7.0 vs 18.6 ± 8.5 days, p = 0.001) and spent less time in hospital (23.7 ± 10.9 vs 32.0 ± 17.6 days, p = 0.009). Duration of antibiotic administration was also significantly shorter in the filgrastim group (13.6 ± 7.6 vs 29.1 ± 19.8 days, p = 0.001). Conclusion: In patients undergoing PBSCT following high-dose chemotherapy, filgrastim significantly reduced the duration of neutropenia, thrombocytopenia and days of G-CSF administration, and led to earlier hospital discharge compared with lenograstim.
Key words: :